Literature DB >> 23888404

Hypertrophy signaling pathways in experimental chronic aortic regurgitation.

Niels Thue Olsen1, Veronica L Dimaano, Thomas Fritz-Hansen, Peter Sogaard, Khalid Chakir, Kristian Eskesen, Charles Steenbergen, David A Kass, Theodore P Abraham.   

Abstract

The development of left ventricular hypertrophy and dysfunction in aortic regurgitation (AR) has only been sparsely studied experimentally. In a new model of chronic AR in rats, we examined activation of molecular pathways involved in myocardial hypertrophy. Chronic AR was produced by damaging one or two valve cusps, resulting in eccentric remodeling and left ventricular dysfunction, with no increase in overall fibrosis. Western blotting showed increased activation of Akt and p38 at 12 weeks and of c-Jun amino-terminal kinase at 2 weeks, decreased activation of extracellular regulated kinase 5 at both 2 and 12 weeks, while activation of calcium/calmodulin-dependent protein kinase II and extracellular regulated kinase 1/2 was unchanged. Expression of calcineurin and ANF was also unchanged. Eccentric hypertrophy and early cardiac dysfunction in experimental AR are associated with a pattern of activation of intracellular pathways different from that seen with pathological hypertrophy in pressure overload, and more similar to that associated with benign physiological hypertrophy.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23888404     DOI: 10.1007/s12265-013-9503-y

Source DB:  PubMed          Journal:  J Cardiovasc Transl Res        ISSN: 1937-5387            Impact factor:   4.132


  36 in total

Review 1.  Mitogen-activated protein kinase signaling in the heart: angels versus demons in a heart-breaking tale.

Authors:  Beth A Rose; Thomas Force; Yibin Wang
Journal:  Physiol Rev       Date:  2010-10       Impact factor: 37.312

2.  A high-fructose diet worsens eccentric left ventricular hypertrophy in experimental volume overload.

Authors:  Andrée-Anne Bouchard-Thomassin; Dominic Lachance; Marie-Claude Drolet; Jacques Couet; Marie Arsenault
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-10-22       Impact factor: 4.733

3.  Calcineurin expression, activation, and function in cardiac pressure-overload hypertrophy.

Authors:  H W Lim; L J De Windt; L Steinberg; T Taigen; S A Witt; T R Kimball; J D Molkentin
Journal:  Circulation       Date:  2000-05-23       Impact factor: 29.690

Review 4.  Valvular heart disease: aortic regurgitation.

Authors:  Raffi Bekeredjian; Paul A Grayburn
Journal:  Circulation       Date:  2005-07-05       Impact factor: 29.690

5.  Experimental aortic regurgitation in rats under echocardiographic guidance.

Authors:  Marie Arsenault; Eric Plante; Marie-Claude Drolet; Jacques Couet
Journal:  J Heart Valve Dis       Date:  2002-01

6.  Effectiveness of beta-blockade in experimental chronic aortic regurgitation.

Authors:  Eric Plante; Dominic Lachance; Martin Gaudreau; Marie-Claude Drolet; Elise Roussel; Marie Arsenault; Jacques Couet
Journal:  Circulation       Date:  2004-09-07       Impact factor: 29.690

7.  Left ventricular diastolic and systolic performance during chronic experimental aortic regurgitation.

Authors:  N M Magid; D C Wallerson; J S Borer; A Mukherjee; M S Young; R B Devereux; J N Carter
Journal:  Am J Physiol       Date:  1992-07

8.  Angiotensin-converting enzyme inhibitor captopril prevents volume overload cardiomyopathy in experimental chronic aortic valve regurgitation.

Authors:  Eric Plante; Martin Gaudreau; Dominic Lachance; Marie-Claude Drolet; Elise Roussel; Cindy Gauthier; Evelyne Lapointe; Marie Arsenault; Jacques Couet
Journal:  Can J Physiol Pharmacol       Date:  2004-03       Impact factor: 2.273

9.  Activation of distinct signal transduction pathways in hypertrophied hearts by pressure and volume overload.

Authors:  T Miyamoto; Y Takeishi; H Takahashi; T Shishido; T Arimoto; H Tomoike; I Kubota
Journal:  Basic Res Cardiol       Date:  2004-07-21       Impact factor: 17.165

10.  Heart failure due to chronic experimental aortic regurgitation.

Authors:  N M Magid; G Opio; D C Wallerson; M S Young; J S Borer
Journal:  Am J Physiol       Date:  1994-08
View more
  5 in total

1.  Molecular Mechanisms and New Treatment Paradigm for Atrial Fibrillation.

Authors:  Padmini Sirish; Ning Li; Valeriy Timofeyev; Xiao-Dong Zhang; Lianguo Wang; Jun Yang; Kin Sing Stephen Lee; Ahmed Bettaieb; Sin Mei Ma; Jeong Han Lee; Demetria Su; Victor C Lau; Richard E Myers; Deborah K Lieu; Javier E López; J Nilas Young; Ebenezer N Yamoah; Fawaz Haj; Crystal M Ripplinger; Bruce D Hammock; Nipavan Chiamvimonvat
Journal:  Circ Arrhythm Electrophysiol       Date:  2016-05

2.  Assessing the role of extracellular signal-regulated kinases 1 and 2 in volume overload-induced cardiac remodelling.

Authors:  Svenja Jochmann; Manar Elkenani; Belal A Mohamed; Eric Buchholz; Dawid Lbik; Lutz Binder; Kristina Lorenz; Ajay M Shah; Gerd Hasenfuß; Karl Toischer; Moritz Schnelle
Journal:  ESC Heart Fail       Date:  2019-07-19

3.  Puerarin attenuates isoproterenol‑induced myocardial hypertrophy via inhibition of the Wnt/β‑catenin signaling pathway.

Authors:  Xiaoying Wang; Kai He; Linlin Ma; Lan Wu; Yan Yang; Yanfei Li
Journal:  Mol Med Rep       Date:  2022-08-10       Impact factor: 3.423

4.  Sildenafil treatment attenuates ventricular remodeling in an experimental model of aortic regurgitation.

Authors:  Kristian Eskesen; Niels Thue Olsen; Veronica L Dimaano; Thomas Fritz-Hansen; Peter Sogaard; Khalid Chakir; Charles Steenbergen; David Kass; Theodore P Abraham
Journal:  Springerplus       Date:  2015-10-13

5.  Left ventricular response in the transition from hypertrophy to failure recapitulates distinct roles of Akt, β-arrestin-2, and CaMKII in mice with aortic regurgitation.

Authors:  Jian Wu; Jieyun You; Xiaoyan Wang; Shijun Wang; Jiayuan Huang; Qihai Xie; Baoyong Gong; Zhiwen Ding; Yong Ye; Cong Wang; Le Kang; Ran Xu; Yang Li; Ruizhen Chen; Aijun Sun; Xiangdong Yang; Hong Jiang; Fenghua Yang; Peter H Backx; Junbo Ge; Yunzeng Zou
Journal:  Ann Transl Med       Date:  2020-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.